# US 2021/0171946 A1 · COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171946 A1
- Document ID: US20210171946A1
- Status: Published application
- Kind: A1
- Application number: 17/069,926
- Filed: 2020-10-14
- Published: 2021-06-10
- Earliest claimed: 2016-06-10
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Nader Najafian; Jae Kim; Mustafa Varoglu; Gabriel Robbie
- Web page: https://patentgrep.com/patent/US20210171946A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2320/31: Combination therapy
- C12N 2320/35: based on a specific dosage / administration regimen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.

## Claims

### Claim 1

A method for treating a subject having paroxysmal nocturnal hemoglobinuria (PNH), the method selected from the group consisting of
a) a method, comprising administering to an eculizumab naïve subject a 200-400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
b) a method, comprising administering to an eculizumab naïve subject a 200-400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
c) a method, comprising administering to an eculizumab naïve subject a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week for 10-15 weeks, followed by a 400 mg fixed dose of the dsRNA agent once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
d) a method, comprising administering to an eculizumab naïve subject a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month for 2 to 4 months; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
e) a method, comprising administering to an eculizumab naïve subject a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject; and
f) a method, comprising administering to an eculizumab naïve subject a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject.

### Claim at position 2

-6. (canceled)

### Claim 7

A method for treating a subject having paroxysmal nocturnal hemoglobinuria (PNH), the method selected from the group consisting of
a) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
b) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
c) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week for 2-8 weeks; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
d) a method, comprising administering to a subject previously treated with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month for 1-2 months; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
e) a method, comprising administering to a subject previously treated with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
f) a method, comprising administering to a subject previously treated with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
g) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
h) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 200 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject;
i) a method, comprising administering to a subject that has not responded to treatment with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every week; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject; and
j) a method comprising administering to a subject that has not responded to treatment with eculizumab, a 400 mg fixed dose of a double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 once every month; and
administering to the subject, a dose of about 300 mg to about 900 mg of eculizumab, or an antigen-binding fragment thereof,
wherein the dsRNA agent comprises a sense strand and an antisense strand, and
wherein the sense strand comprises 5′-asasGfcAfaGfaUfAfUfuUfuuAfuAfaua-3′ (SEQ ID NO:2876) and the antisense strand comprises 5′-usAfsUfuAfuaAfaAfauaUfcUfuGfcuususudTdT-3′ (SEQ ID NO:2889),
wherein a, g, c and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively; Af, Gf, Cf and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively; dT is a deoxy-thymine nucleotide; and s is a phosphorothioate linkage, thereby treating the subject.

### Claim at position 4

-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the dose of eculizumab, or an antigen-binding fragment thereof, is about 25% to about 75% of the eculizumab maintenance label dose.

### Claim 18 (depends on 17)

The method of claim 17, wherein the dose of eculizumab, or an antigen-binding fragment thereof, is 300 mg to 600 mg or 600 mg to 900 mg.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the frequency of administration of eculizumab is reduced as compared to the frequency of administration required by the label.

### Claim 21 (depends on 20)

The method of claim 20, wherein eculizumab is administered to the subject once every four weeks, every 2 months, every 3 months, every 4 months, every 5 months or every 6 months.

### Claim 22 (depends on 1)

The method of claim 1, wherein the eculizumab, or an antigen-binding fragment thereof, is administered to the subject as a 600 mg fixed dose once every four weeks; a 300 mg fixed dose once every four weeks; or a 900 mg fixed dose once every four weeks.

### Claim 23

(canceled)

### Claim 24 (depends on 7)

The method of claim 7, wherein the eculizumab, or an antigen-binding fragment thereof, is administered to the subject as a 600 mg fixed dose once every four weeks; as a 900 mg fixed dose once every four weeks, or as a 900 mg fixed dose every other week.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 7)

The method of claim 7, wherein the eculizumab, or an antigen-binding fragment thereof, treatment to which the subject did not respond comprised administration to the subject of a 1200 mg fixed dose every other week.

### Claim at position 16

-30. (canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein the treatment prevents breakthrough hemolysis in the subject reduces the mean maximum C5 mRNA level by at least about 98% relative to baseline; lowers the minimum residual C5 level to about 1.0 micrograms/ml or below; lowers the classical complement pathway (CCP) activity by at least about 94% relative to baseline; inhibits the mean maximum hemolysis, as measured by inhibition of sheep red blood cell hemolysis, by at least about 75% relative to baseline; or lowers the level of lactate dehydrogenase (LDH) in the subject to levels lower than about 1.5 times the upper limit of normal (ULN).

### Claim at position 18

-41. (canceled)

### Claim 42 (depends on 1)

The method of claim 1, wherein the dsRNA agent further comprises a ligand.

### Claim 43 (depends on 42)

The method of claim 42, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

### Claim 44 (depends on 42)

The method of claim 42, wherein the ligand is

### Claim 45 (depends on 42)

The method of claim 42, wherein the ligand is attached to the 3′ end of the sense strand.

### Claim 46 (depends on 45)

The method of claim 45, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic

### Claim at position 24

-49. (canceled)

### Claim 50 (depends on 7)

The method of claim 7, wherein the dsRNA agent further comprises a ligand.

### Claim 51 (depends on 50)

The method of claim 50, wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

### Claim 52 (depends on 50)

The method of claim 50, wherein the ligand is

### Claim 53 (depends on 50)

The method of claim 50, wherein the ligand is attached to the 3′ end of the sense strand.

### Claim 54 (depends on 53)

The method of claim 53, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic
